MRI透明细胞可能性评分对cT1a与cT1b实性肾脏肿物定性诊断效能及阅片者间一致性的外部验证研究
回顾性纳入102例患者共108个≤7 cm实性肾脏肿物(83个cT1a、25个cT1b),由3名腹部放射科医师独立应用ccLS v2.0评分。以评分≥4预测ccRCC,cT1a中位敏感度85%、特异度82%、准确率83%,cT1b为82%、100%、92%;阅片者间一致性kappa在cT1a与cT1b分别为0.82与0.83。
要点
- ccLS≥4预测ccRCC:cT1a敏感度85%、特异度82%、准确率83%,cT1b为82%、100%、92%。
- ccRCC占比随评分升高:cT1a在ccLS 1–5分别为0%、0%、20%、68%、93%,cT1b为0%、0%、32%、90%、100%。
- 阅片者间一致性:ccLS≥4时cT1a与cT1b的kappa分别为0.82与0.83,ccLS 1–5整体分别为0.65与0.62。
核心结论
- 本研究对ccLS进行了外部验证,总体诊断效能与阅片者间一致性较高;ccLS为MRI无创诊断ccRCC提供了标准化方法。
研究设计与样本
- 回顾性研究纳入2013年1月至2018年2月行多参数MRI的102例患者(67男、35女,平均年龄56.9±12.8岁),共108个(≥25%强化组织)≤7 cm实性肾脏肿物(83个cT1a[≤4 cm]、25个cT1b[>4 cm且≤7 cm]),均有组织学诊断,由3名腹部放射科医师独立应用ccLS v2.0评分。
诊断标准与关键数值
- 以ccLS≥4预测ccRCC,cT1a中位敏感度85%、特异度82%、准确率83%,cT1b为82%、100%、92%。
临床应用与阅片要点
- 作者认为ccLS为MRI无创诊断ccRCC提供了标准化方法,可用于实性肾脏肿物的非侵入性鉴别。
局限性
- 原文在背景中提出ccLS仍需进一步外部验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND. The clear cell likelihood score (ccLS) has been proposed for the noninvasive differentiation of clear cell renal cell carcinoma (ccRCC) from other renal neoplasms on multiparametric MRI (mpMRI), though further external validation remains needed. OBJECTIVE. The purpose of our study was to evaluate the diagnostic performance and interreader agreement of the ccLS version 2.0 (v2.0) for characterizing solid renal masses as ccRCC. METHODS. This retrospective study included 102 patients (67 men, 35 women; mean age, 56.9 ± 12.8 [SD] years) who underwent mpMRI between January 2013 and February 2018, showing a total of 108 (≥ 25% enhancing tissue) solid renal masses measuring 7 cm or smaller (83 cT1a [≤ 4 cm] and 25 cT1b [> 4 cm and ≤ 7 cm]), all with a histologic diagnosis. Three abdominal radiologists independently reviewed the MRI examinations using ccLS v2.0. Median reader sensitivity, specificity, and accuracy were computed for predicting ccRCC by ccLS of 4 or greater, and individual reader AUCs were derived. The percentage of masses that were ccRCC was calculated, stratified by ccLS. Interobserver agreement was assessed by the Fleiss kappa statistic. RESULTS. The sample included 45 ccRCCs (34 cT1a, 11 cT1b), 30 papillary renal cell carcinomas (RCCs), 13 chromophobe RCCs, 14 oncocytomas, and six fat-poor angiomyolipomas. Median reader sensitivity, specificity, and accuracy for predicting ccRCC by ccLS of 4 or greater were 85%, 82%, and 83% among cT1a masses and 82%, 100%, and 92% among cT1b masses. The three readers' AUCs for predicting ccRCC by ccLS for cT1a masses were 0.90, 0.84, and 0.89 and for cT1b masses were 0.99, 0.97, and 0.92. Across readers, the percentage of masses that were ccRCC among cT1a masses was 0%, 0%, 20%, 68%, and 93% for ccLS of 1, 2, 3, 4, and 5, respectively; among cT1b masses, the percentage of masses that were ccRCC was 0%, 0%, 32%, 90%, and 100% for ccLS of 1, 2, 3, 4, and 5, respectively. Interobserver agreement among cT1a and cT1b masses for ccLS of 4 or greater was 0.82 and 0.83 and for ccLS of 1-5 overall was 0.65 and 0.62, respectively. CONCLUSION. This study provides external validation of the ccLS, finding overall high measures of diagnostic performance and interreader agreement. CLINICAL IMPACT. The ccLS provides a standardized approach to the noninvasive diagnosis of ccRCC by MRI.
引用
- Dunn, Linehan, Clarke, et al. Diagnostic Performance and Interreader Agreement of the MRI Clear Cell Likelihood Score for Characterization of cT1a and cT1b Solid Renal Masses: An External Validation Study. AJR Am J Roentgenol. 2022. PMID: 35642765. doi:10.2214/AJR.22.27378
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。